PET/CT Scanner Financing

PET/CT combines metabolic imaging from the positron emission tomography component with anatomic localization from the CT component, and that combination defines its clinical value: you see where the metabolism is and exactly where in the body it is happening. For oncology staging, restaging, treatment response, and certain cardiac and neurological indications, the study type is difficult to replicate with any single modality. The reimbursement per study reflects that clinical indispensability.

Financing a PET/CT system involves a different set of operational considerations than a standalone CT purchase. Radiopharmaceutical supply chain, cyclotron access or delivery logistics, radiation safety infrastructure, and NRC or state licensing requirements all factor into the total project cost that needs to be financed. A complete PET/CT program budget includes the scanner, the site preparation, and often significant facility modification costs that belong in the financed package from the start.

PET/CT System Market: Platforms, Generations, and Pricing

The PET/CT market is concentrated among a few major manufacturers. Siemens Healthineers, GE HealthCare, Philips, and Canon Medical are the primary platform providers for clinical PET/CT systems. New systems range from approximately $1,000,000 for entry-level configurations to $2,500,000+ for long-axial-field-of-view systems and digital SiPM-detector platforms that represent the current generation standard.

The used and refurbished PET/CT market is active, driven by hospitals and imaging centers upgrading from older PMT-based systems to current digital SiPM platforms. A late-model certified-refurbished PET/CT with SiPM detector technology can price in the $500,000-$900,000 range, which compresses the capital cost significantly compared to new-system pricing while delivering much of the sensitivity and resolution improvement of the current generation.

• New PET/CT: typically $1,000,000-$2,500,000+ depending on detector technology and configuration
• Certified-refurbished SiPM PET/CT: typically $500,000-$900,000
• All transactions in this tier require full financial underwriting
• Radiopharmaceutical logistics and site preparation are significant additional costs that should be budgeted alongside the scanner

Long-axial-field-of-view PET/CT systems, including the Siemens Biograph Vision Quadra and the GE SIGNA PET/MR family for those evaluating hybrid systems, represent a new tier of capital commitment in the PET imaging world. At $3,000,000+ for flagship long-axial-FOV systems, these acquisitions are health system capital decisions rather than practice-level ones, but the financing structures we work with extend to that tier as well. More relevant for most outpatient oncology programs is the standard whole-body FOV PET/CT in the $1,000,000-$1,800,000 range for current SiPM-equipped systems, which is where the majority of community oncology and radiology center acquisitions occur.

Structuring a PET/CT Transaction

PET/CT acquisitions above $400,000, which covers virtually all transactions in this category, require full financial underwriting. The lender will review two years of business financial statements, interim P&L and balance sheet, bank statements, and principal personal financials. The underwrite for an oncology center or hospital department will also look at the payer mix for PET/CT studies, since this significantly affects the reimbursement per study and the debt service coverage ratio.

Site preparation for a PET/CT suite can add $200,000-$500,000 to the total project cost, including radiation shielding, HVAC modifications, hot lab construction for radiopharmaceutical handling, a dose calibrator, and waste handling infrastructure. These costs should be included in the financed package. See our detailed page on CT scanner installation and shielding financing, which covers radiation shielding requirements that apply to PET/CT as well.

First-year depreciation planning on a $1,500,000+ acquisition is highly consequential and should be modeled before the transaction closes. The combination of Section 179 and bonus depreciation, where applicable in the acquisition year, can produce a substantial after-tax first-year benefit.

Practices acquiring PET/CT for the first time should budget not just the scanner and site preparation but also the working capital required to fund the radiopharmaceutical costs until the first round of reimbursements arrives. FDG delivery costs, cyclotron access fees or unit-dose delivery contract fees, and the staffing cost of a certified nuclear medicine technologist are ongoing program costs that begin with the first patient scan. A PET/CT program that is financially well-prepared for the first 90 to 120 days of operation, before Medicare payments begin to flow at cycle, will avoid the cash flow stress that catches first-time nuclear medicine program operators off guard. Working capital financing, available separately from the equipment acquisition, can cover this ramp period if needed.

Facilities That Operate PET/CT Programs

Oncology centers and cancer institutes are the core market. PET/CT is integral to staging, treatment planning, and response assessment for most solid tumors and lymphoma. A center treating patients for whom PET/CT is a standard-of-care part of the diagnostic pathway has a built-in utilization base that makes the acquisition economically predictable.

Radiology groups operating standalone imaging centers in markets where a PET/CT program can attract oncology referrals find that the capital investment supports a revenue line that differentiates their facility from competitors without nuclear medicine capability. The administrative and regulatory infrastructure required to operate a PET program is a barrier to entry that works in favor of centers that clear it.

Academic medical centers and large regional hospitals operating nuclear medicine departments as part of a comprehensive imaging service see PET/CT as standard infrastructure. The financing at these institutions sometimes goes through health system capital processes rather than traditional equipment financing, and we work within those structures.

Independent outpatient imaging centers in markets without convenient hospital-based PET/CT access have a clear referral opportunity. Oncologists who currently refer patients to a hospital that is inconveniently located, expensive on a per-study basis, or difficult to schedule promptly will refer to an independent center that removes those friction points. The capital investment required to establish a PET/CT program at an outpatient imaging center is significant, but the competitive moat it creates in an underserved market is also significant. The financial model for this scenario depends heavily on referral volume projections from specific oncology practices, and documenting those referral relationships is an important part of the underwriting presentation.

Neurology and memory disorder programs are a smaller but clinically meaningful PET/CT user group, leveraging amyloid and tau PET imaging for Alzheimer's disease assessment. The radiopharmaceutical and reimbursement landscape for neurology PET is distinct from oncology PET, and practices focused on this application should discuss the specific CPT and coverage issues for amyloid PET with their billing team before building the acquisition business case.

Frequently Asked Questions

Questions from facilities evaluating a PET/CT acquisition and its financing.

Discuss PET/CT Financing

Share the system you are evaluating and the expected acquisition cost including site prep. We will respond with a preliminary financing framework within one business day.